Trial · NCT02615002
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Run-In Phase (2 Weeks) | STARTED | Experimental: Piromelatine 5 mg | 89 | |
| Run-In Phase (2 Weeks) | STARTED | Experimental: Piromelatine 20 mg | 88 | |
| Run-In Phase (2 Weeks) | STARTED | Experimental: Piromelatine 50 mg | 88 | |
| Run-In Phase (2 Weeks) | STARTED | Placebo Comparator | 106 | |
| Run-In Phase (2 Weeks) | COMPLETED | Experimental: Piromelatine 5 mg | 89 | |
| Run-In Phase (2 Weeks) | COMPLETED | Experimental: Piromelatine 20 mg | 88 | |
| Run-In Phase (2 Weeks) | COMPLETED | Experimental: Piromelatine 50 mg | 88 | |
| Run-In Phase (2 Weeks) | COMPLETED | Placebo Comparator | 106 | |
| Run-In Phase (2 Weeks) | NOT COMPLETED | Experimental: Piromelatine 5 mg | 0 | |
| Run-In Phase (2 Weeks) | NOT COMPLETED | Experimental: Piromelatine 20 mg | 0 | |
| Run-In Phase (2 Weeks) | NOT COMPLETED | Experimental: Piromelatine 50 mg | 0 | |
| Run-In Phase (2 Weeks) | NOT COMPLETED | Placebo Comparator | 0 | |
| Double Blind Dose Escalation (26 Weeks) | STARTED | Experimental: Piromelatine 5 mg | 89 | |
| Double Blind Dose Escalation (26 Weeks) | STARTED | Experimental: Piromelatine 20 mg | 88 | |
| Double Blind Dose Escalation (26 Weeks) | STARTED | Experimental: Piromelatine 50 mg | 88 | |
| Double Blind Dose Escalation (26 Weeks) | STARTED | Placebo Comparator | 106 | |
| Double Blind Dose Escalation (26 Weeks) | Number of Baseline Participants | Experimental: Piromelatine 5 mg | 83 | |
| Double Blind Dose Escalation (26 Weeks) | Number of Baseline Participants | Experimental: Piromelatine 20 mg | 87 | |
| Double Blind Dose Escalation (26 Weeks) | Number of Baseline Participants | Experimental: Piromelatine 50 mg | 80 | |
| Double Blind Dose Escalation (26 Weeks) | Number of Baseline Participants | Placebo Comparator | 102 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02615002/flow